Market Overview:
The global mRNA vaccines for infectious diseases market is expected to grow at a CAGR of over 20% during the forecast period from 2018 to 2030. The increasing prevalence of infectious diseases, rising demand for better and innovative vaccines, and technological advancements are some of the major factors that are expected to drive the growth of this market. The global mRNA vaccines for infectious diseases market can be segmented on the basis of type into infectious disease vaccines and cancer vaccines. The cancer vaccine segment is expected to grow at a higher CAGR than the infectious disease vaccine segment during the forecast period from 2018 to 2030. This is due to increasing awareness about various types of cancers and their prevention among people across the globe. On the basis of application,the global mRNA vaccines for infectious diseases market can be divided into two segments:infectious disease and cancer. The infection disease segment is anticipated witness a higher growth rate as compared with Cancer Vaccine Segment over next few years owing growing incidences rates HPV & other Infectious Diseases such as Influenza (Flu), Diphtheria etc., globally . However, in terms revenue generated by sales Cancer Vaccines will continue dominate Global Market throughout Forecast Period .Geographically, North America dominates this market followed by Europe; however Asia Pacific region is projected show highest CAGR over next few years owing growing incidences rates HPV & other Infectious Diseases such as Influenza (Flu), Diphtheria etc.
Product Definition:
mRNA vaccines are viral vectors that deliver pieces of genetic code from the virus or disease you are trying to vaccinate against into your cells. Once inside your cells, these genetic instructions get turned into proteins, which then help prepare your immune system to recognize and fight infection from the real virus or disease.
Importantly, mRNA vaccines can be customized to include pieces of any virus or disease, meaning they could potentially be used to vaccinate against any pathogen. This makes them a very versatile tool for vaccine development, and several different mRNA vaccine candidates are currently in clinical trials for a variety of diseases.
Infectious Disease Vaccines:
Infectious diseases are those that are caused by pathogens (e.g., bacteria, viruses, fungi) and their toxins. The most common types of infectious diseases include cholera, typhoid fever, dengue hemorrhagic fever, hepatitis A & B (janitorial staff at workplaces), influenza (flu), measles/mumps/rubella (MMR) and chickenpox.
Cancer Vaccines:
Cancer vaccines are substances that can stimulate the body's immune system to fight cancer. There are two types of vaccines: attenuated and inactivated. Attenuated vaccine contains a weakened form of the disease-causing agent, which makes it much easier for the body's immune system to recognize and attack cancer cells as if they were normal cells.
Application Insights:
Based on the application, the market is segmented into infectious disease and cancer. The infectious diseases segment dominated the overall industry in terms of revenue share in 2017. This can be attributed to a high prevalence of chronic infections that lead to increased demand for efficient vaccines. Moreover, an increase in global travel patterns has led to an increased risk of exposure to new viral and bacterial pathogens, which further boosts product demand globally.
The cancer segment is expected to witness lucrative growth over the forecast period owing to increasing awareness about early detection and treatment procedures coupled with a rise in incidence rates across various regions including North America, Europe and Asia Pacific since 1980s & 1990s respectively. According these statistics from WHO; it was estimated that around 1 million people died due either TO or FROM cancer every year till 2015 worldwide (in 2014).
Regional Analysis:
North America dominated the global mRNA vaccines for infectious diseases market in 2017. This is due to the presence of a large number of biopharmaceutical companies, which are engaged in developing and commercializing these products. The U.S.-based companies include Moderna Therapeutics, Inc.; NantHealth LLC; and Bluebird Bio Inc., among others (Table 1).
The Asia Pacific is expected to be one of the fastest-growing regions during the forecast period owing to rising investments by governments as well as private players for improving healthcare infrastructure in this region coupled with increasing prevalence of chronic infectious diseases such as HIV/AIDS, cancer, diabetes & obesity (Metabolic Syndrome), etc. In addition, growing awareness about early diagnosis and treatment programs will drive regional growth further. For instance, Novartis AG has extended its support for CVD research program that focuses on exploring potential immunotherapies against COVID-19 virus infection using mRNA interference technology [6].
Growth Factors:
- Increasing incidence of infectious diseases: The increasing incidence of infectious diseases is one of the key growth drivers for the mRNA vaccines market. Infectious diseases are caused by pathogenic microorganisms such as bacteria, viruses, and parasites. These infections can cause a wide range of symptoms, depending on the type and severity of infection. The increasing incidence of infectious diseases due to factors such as globalization, changing lifestyles, and environmental degradation is expected to drive the demand for mRNA vaccines in the coming years.
- Growing awareness about benefits offered by mRNA vaccines: There is a growing awareness about the benefits offered by mRNA vaccines among healthcare professionals and patients across the globe. This is likely to boost demand for these vaccines in the coming years.
- Technological advancements in vaccine development: The technological advancements in vaccine development are another key factor driving growth for this market segmentation over other segments within life sciences sector Vaccine developers are increasingly using cutting-edge technologies such as CRISPR-Cas9 gene editing system to develop novel therapies that can offer better protection against various infections Diseases that were once considered difficult or impossible to treat are now becoming more manageable with new therapeutic approaches being developed on an ongoing basis This will create opportunities for players operating in this market over next few years 4 Emerging economies offer high potential growth opportunities: A large number of emerging economies offer high potential growth opportunities owing to their large population base and unmet medical needs In addition, these countries also have favorable reimbursement policies which will help support
Scope Of The Report
Report Attributes
Report Details
Report Title
mRNA Vaccines for Infectious Diseases Market Research Report
By Type
Infectious Disease Vaccines, Cancer Vaccines
By Application
Infectious Disease, Cancer
By Companies
Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
249
Number of Tables & Figures
175
Customization Available
Yes, the report can be customized as per your need.
Global mRNA Vaccines for Infectious Diseases Market Report Segments:
The global mRNA Vaccines for Infectious Diseases market is segmented on the basis of:
Types
Infectious Disease Vaccines, Cancer Vaccines
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Infectious Disease, Cancer
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Moderna Therapeutics
- CureVac
- Translate Bio
- BioNTech
- Sangamo Therapeutics
- Argos Therapeutics
- In-Cell-Art
- eTheRNA
- Ethris
- Tiba Biotechnology
Highlights of The mRNA Vaccines for Infectious Diseases Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Infectious Disease Vaccines
- Cancer Vaccines
- By Application:
- Infectious Disease
- Cancer
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the mRNA Vaccines for Infectious Diseases Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
mRNA vaccines are vaccines that use pieces of the genetic code of a virus or other infectious agent to help the body build immunity. This type of vaccine is often used to protect people against diseases like flu, measles, and chickenpox.
Some of the key players operating in the mrna vaccines for infectious diseases market are Moderna Therapeutics, CureVac, Translate Bio, BioNTech, Sangamo Therapeutics, Argos Therapeutics, In-Cell-Art, eTheRNA, Ethris, Tiba Biotechnology.
The mrna vaccines for infectious diseases market is expected to register a CAGR of 20%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 mRNA Vaccines for Infectious Diseases Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 mRNA Vaccines for Infectious Diseases Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 mRNA Vaccines for Infectious Diseases Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the mRNA Vaccines for Infectious Diseases Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global mRNA Vaccines for Infectious Diseases Market Size & Forecast, 2018-2028
4.5.1 mRNA Vaccines for Infectious Diseases Market Size and Y-o-Y Growth
4.5.2 mRNA Vaccines for Infectious Diseases Market Absolute $ Opportunity
Chapter 5 Global mRNA Vaccines for Infectious Diseases Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 mRNA Vaccines for Infectious Diseases Market Size Forecast by Type
5.2.1 Infectious Disease Vaccines
5.2.2 Cancer Vaccines
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global mRNA Vaccines for Infectious Diseases Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 mRNA Vaccines for Infectious Diseases Market Size Forecast by Applications
6.2.1 Infectious Disease
6.2.2 Cancer
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global mRNA Vaccines for Infectious Diseases Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 mRNA Vaccines for Infectious Diseases Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America mRNA Vaccines for Infectious Diseases Analysis and Forecast
9.1 Introduction
9.2 North America mRNA Vaccines for Infectious Diseases Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America mRNA Vaccines for Infectious Diseases Market Size Forecast by Type
9.6.1 Infectious Disease Vaccines
9.6.2 Cancer Vaccines
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America mRNA Vaccines for Infectious Diseases Market Size Forecast by Applications
9.10.1 Infectious Disease
9.10.2 Cancer
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe mRNA Vaccines for Infectious Diseases Analysis and Forecast
10.1 Introduction
10.2 Europe mRNA Vaccines for Infectious Diseases Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe mRNA Vaccines for Infectious Diseases Market Size Forecast by Type
10.6.1 Infectious Disease Vaccines
10.6.2 Cancer Vaccines
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe mRNA Vaccines for Infectious Diseases Market Size Forecast by Applications
10.10.1 Infectious Disease
10.10.2 Cancer
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific mRNA Vaccines for Infectious Diseases Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific mRNA Vaccines for Infectious Diseases Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific mRNA Vaccines for Infectious Diseases Market Size Forecast by Type
11.6.1 Infectious Disease Vaccines
11.6.2 Cancer Vaccines
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific mRNA Vaccines for Infectious Diseases Market Size Forecast by Applications
11.10.1 Infectious Disease
11.10.2 Cancer
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America mRNA Vaccines for Infectious Diseases Analysis and Forecast
12.1 Introduction
12.2 Latin America mRNA Vaccines for Infectious Diseases Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America mRNA Vaccines for Infectious Diseases Market Size Forecast by Type
12.6.1 Infectious Disease Vaccines
12.6.2 Cancer Vaccines
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America mRNA Vaccines for Infectious Diseases Market Size Forecast by Applications
12.10.1 Infectious Disease
12.10.2 Cancer
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) mRNA Vaccines for Infectious Diseases Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) mRNA Vaccines for Infectious Diseases Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) mRNA Vaccines for Infectious Diseases Market Size Forecast by Type
13.6.1 Infectious Disease Vaccines
13.6.2 Cancer Vaccines
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) mRNA Vaccines for Infectious Diseases Market Size Forecast by Applications
13.10.1 Infectious Disease
13.10.2 Cancer
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 mRNA Vaccines for Infectious Diseases Market: Competitive Dashboard
14.2 Global mRNA Vaccines for Infectious Diseases Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Moderna Therapeutics
14.3.2 CureVac
14.3.3 Translate Bio
14.3.4 BioNTech
14.3.5 Sangamo Therapeutics
14.3.6 Argos Therapeutics
14.3.7 In-Cell-Art
14.3.8 eTheRNA
14.3.9 Ethris
14.3.10 Tiba Biotechnology
